AH

Majesco’s Utilant Acquisition Celebrates Two Years of Disruptive Market Success in Risk Management and Data and Analytics

Retrieved on: 
Tuesday, August 29, 2023
Professional Services, Technology, Data Analytics, Insurance, Software, Artificial Intelligence, Intelligence, Communication, Software as a service, LC, Foot, Risk management, P&C, Android, Organization, AH, Acquisition, FIN Atlantic Film Festival, Machine learning, Data, Risk, Apple, Growth, AI, Seamlessly loopable, Loss-control consultant, Data Analytics Library, Automation, Medical device, Retail, Asset management, Mobile phone, Dynamic line rating for electric utilities, Majesco Entertainment

Majesco launched an innovative Data and Analytics business unit combining Utilant’s technology and data scientists with Majesco’s market-leading solutions, resulting in an array of new, innovative solutions.

Key Points: 
  • Majesco launched an innovative Data and Analytics business unit combining Utilant’s technology and data scientists with Majesco’s market-leading solutions, resulting in an array of new, innovative solutions.
  • Data, effectively used, will always have value as analytics’ capabilities stand to be a game-changer for insurance.
  • When new, real-time data, advanced analytics, AI/machine learning, and generative AI are effectively combined, insurers can have a significant impact across the entire insurance value chain.
  • Business Intelligence – Offering unified insurance data & analytics solution by embedding business intelligence and AI/ML insights inside core insurance workflows.

Revolutionize the Customer Experience: New Majesco Report Spotlights Accelerated Evolution of L&AH to Meet Dynamic Expectations

Retrieved on: 
Tuesday, August 22, 2023
Professional Services, Data Management, Technology, Data Analytics, Insurance, Software, Organization, Metal, Ecosystem, AH, P&C, Luigi, Millennials, Risk, Generation Z, Management, Risk management, Majesco Entertainment

The impact for insurers is a need to align with the changing needs and expectations, including new products, value-added services, flexibility of benefits, and more to meet these new and higher standards.

Key Points: 
  • The impact for insurers is a need to align with the changing needs and expectations, including new products, value-added services, flexibility of benefits, and more to meet these new and higher standards.
  • “The state of play in the market, from both employers and their employees for group and voluntary benefits, is highly dynamic, posing new challenges for employers and insurers alike.
  • Majesco is the partner P&C and L&AH insurers choose to create and deliver outstanding experiences for customers.
  • We combine our technology and insurance experience to anticipate what is next, without losing sight of what’s important now.

AH Board of Commissioners Approves Budget for 'Putting People First' in 2024

Retrieved on: 
Thursday, June 29, 2023
Commissioner, Plan, Quality of life, AH, Housing, HUD, Wake County Board of Commissioners, Management, Real estate

"I am proud of the work of the AH staff and thankful to my fellow commissioners for approving a budget that invests in the potential of people."

Key Points: 
  • "I am proud of the work of the AH staff and thankful to my fellow commissioners for approving a budget that invests in the potential of people."
  • The FY2024 budget allocates $253 million in housing assistance, a 12 percent increase that supports an expansion of households served amidst higher housing costs in Atlanta.
  • The new budget will also fund 543 new households through AH's Housing Choice and HomeFlex programs.
  • Currently AH provides ongoing housing assistance and support services to 44,000 people in 21,000 households, 96 percent of which are extremely or very-low income.

Atlanta Housing and the Department of Parks and Recreation Unveil Watkins Street Park

Retrieved on: 
Saturday, June 10, 2023
Recreation, Commissioner, Bowen, Demolished public housing projects in Atlanta, Golden Joystick Awards, AH, City, Health, Atlanta Housing Authority, Nightclub

ATLANTA, June 10, 2023 /PRNewswire/ -- Atlanta Housing (AH), in collaboration with the Bowen Choice Neighborhood team and the City of Atlanta, is thrilled to announce the completion and celebration of Watkins Street Park, a striking greenspace designed to cater to all ages and foster community engagement.

Key Points: 
  • ATLANTA, June 10, 2023 /PRNewswire/ -- Atlanta Housing (AH), in collaboration with the Bowen Choice Neighborhood team and the City of Atlanta, is thrilled to announce the completion and celebration of Watkins Street Park, a striking greenspace designed to cater to all ages and foster community engagement.
  • Those of you from the community can likely attest to that," said Commissioner Justin Cutler of the City of Atlanta Parks and Recreation.
  • "On behalf of Mayor Dickens, we thank Atlanta Housing for your leadership and organization in creating this magnificent space."
  • The celebration and ribbon-cutting is open to the public beginning at 11 AM, at 1065 Hightower Road NW, Atlanta, GA 30318 (Watkins Street and Hightower Road).

Women's Health Interactive and AH! YES Announce Partnership Promoting Better Sex With Body-Safe Personal Lubricants

Retrieved on: 
Tuesday, May 23, 2023
Partnership, STI, Infection, Research, Sale, AH, Human, Risk, SAN, PH, FDA, Safety, YES, Birth control, Collaboration

SAN JOSE, Calif., May 23, 2023 /PRNewswire/ -- Women's Health Interactive, an online publisher exclusively focused on fearless conversations about sex and sexuality, has teamed up with AH! YES and their quest to Make Vaginas Happy®.

Key Points: 
  • The company has created specific content including results from hands-on research to educate audiences about these pitfalls and how much better sex can be using the right personal lubricants for specific sexual situations.
  • YES offers a line of intimate care products designed to support vaginal health and better, more comfortable sex.
  • YES will now be featured on all of Women's Health Interactive's medically-reviewed educational articles and reviews relating to personal lubricant safety and information.
  • "We're delighted to embark on this partnership with Women's Health Interactive," said Sarah Brooks, President of AH!

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

Retrieved on: 
Wednesday, May 10, 2023
Driver License Agreement, Neuron, Substantia nigra, PD, Multiple system atrophy, Anosmia, Pathology, Vanderbilt University Medical Center, ASX, PBT2, Vanderbilt University, Disorder, American depositary receipt, Neurotherapeutics, ATH, AH, Animal, Patent, MSA, SAN, Disability studies, Remuneration, Appendix, Disease, Pharmaceutical industry, Alterity

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 FY23).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 FY23).
  • “The Phase 2 trial is gaining momentum with active recruitment in five countries, including the United States.
  • We were pleased that an independent study was published providing further evidence that ATH434 has potential to be neuroprotective in humans.”
    The Company’s cash position on 31 March 2023 was A$21.9M with operating cash outflows of A$4M.
  • In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors’ fees, consulting fees, remuneration and superannuation at commercial rates.

ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis

Retrieved on: 
Thursday, May 4, 2023
ASC, NLRP3, Inflammation, Super Meat Boy, AH, Alcoholic hepatitis, Mouse, Liver, Therapy, Hepatitis, Phosphorus, Liquor

Reported data demonstrate a central role of NLRP3 and ASC in alcohol-induced liver inflammation, and highlight the critical role of extracellular ASC specks in the propagation of systemic and liver inflammation in AH

Key Points: 
  • Reported data demonstrate a central role of NLRP3 and ASC in alcohol-induced liver inflammation, and highlight the critical role of extracellular ASC specks in the propagation of systemic and liver inflammation in AH
    WESTON, Fla., May 04, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal, Hepatology, supporting the critical role of extracellular ASC specks in propagating damaging liver inflammation in AH.
  • In the paper titled, “Alcohol-induced extracellular asc specks perpetuate liver inflammation and damage in alcoholic hepatitis even after alcohol cessation,” the authors reported that alcohol consumption induces NLRP3 inflammasome activation in the liver, and alcohol binges additionally increase circulating extracellular ASC specks and hepatic ASC aggregates leading to perpetuation of damaging inflammation.
  • Given the lack of specific treatment for AH, our data support NLRP3 as a therapeutic target in AH.” To read the article, Click Here .
  • “The research published in Hepatology demonstrating that alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage provides support for targeting inflammasome ASC with IC 100, which has been shown to disrupt the structure and function of both intra- and extracellular ASC specks,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

Retrieved on: 
Thursday, April 27, 2023
Columbia University, Columbia University Irving Medical Center, KOL, Prevalence, Event, Associate, Patient, Biology, Hospital, Alcoholic liver disease, Pharmaceutical industry, AH, Medicine

CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City.

Key Points: 
  • CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City.
  • Dr. Paul Gaglio, Professor of Medicine (in Surgery) and director of Hepatology Outreach at NY-Presbyterian Hospital, Columbia University Irving Medical Center.
  • DURECT's KOL Event will also be broadcast online and can be accessed via the following:
    The webcast links will also be available by accessing DURECT's homepage at www.durect.com and clicking on "Events" under the "Investors" section.
  • A replay will be available following the conclusion of the event.

Majesco and EvolutionIQ Partner to Expand AI-Powered Claims Guidance for Disability Insurance Lines

Retrieved on: 
Thursday, March 30, 2023
Software, Technology, Professional Services, Insurance, Partnership, Disability, L&H, Attention, TPA, Organization, AH, Injury, Environment, Economics, Cryptocurrency, Majesco Entertainment

Majesco, a global leader of cloud insurance platform software for insurance business transformation, today announced a partnership to integrate EvolutionIQ’s AI-powered Claims Guidance platform with Majesco’s suite of disability insurance claims technology solutions.

Key Points: 
  • Majesco, a global leader of cloud insurance platform software for insurance business transformation, today announced a partnership to integrate EvolutionIQ’s AI-powered Claims Guidance platform with Majesco’s suite of disability insurance claims technology solutions.
  • These include Majesco Claims for L&AH and Majesco ClaimVantage Claims for L&H.
  • The integration is part of the Majesco EcoExchange, which is a next-generation marketplace of partner technologies designed to help the insurance industry meet the demands of today’s digital customer.
  • “EvolutionIQ with Majesco Claims solutions for the L&AH segment offers our customers and the industry a significant opportunity to transform the claims dynamics for disability and workers compensation,” said Adam Elster, CEO at Majesco.

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

Retrieved on: 
Tuesday, March 14, 2023
Research, Neurodegenerative disease, Therapy, PBT2, SAN, Patent, ATH, Patient, End-user license agreement, Alzheimer's Association, Disease, United States Patent and Trademark Office, AH, Dementia, Master, Multiple system atrophy, ASX, Atomic mass, Traffic barrier, Pharmaceutical industry, Alzheimer's disease, Alterity, Parkinsonism

MELBOURNE, Australia AND SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted. The patent, entitled “Compounds for and methods of treating diseases” (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.

Key Points: 
  • 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.
  • Alterity also announced a Licensing Agreement for the new patent and a sub-licensing agreement for PBT2 to Professor Colin Masters, M.D., A.O., to advance these compounds for the treatment of Alzheimer’s and related diseases.
  • Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 in Alzheimer’s disease (AD).
  • PBT2 is a low molecular weight drug candidate discovered by Alterity and is currently the Company’s product candidate for Alzheimer’s disease.